Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-cash Items: 2016-2025

Historic Non-cash Items for Altimmune (ALT) over the last 9 years, with Sep 2025 value amounting to $1.1 million.

  • Altimmune's Non-cash Items fell 74.13% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 74.13%. This contributed to the annual value of $3.7 million for FY2024, which is 51.09% up from last year.
  • According to the latest figures from Q3 2025, Altimmune's Non-cash Items is $1.1 million, which was down 75.07% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Non-cash Items registered a high of $25.7 million during Q4 2022, and its lowest value of $3,642 during Q2 2022.
  • Moreover, its 3-year median value for Non-cash Items was $3.7 million (2024), whereas its average is $4.3 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first tumbled by 99.58% in 2022, then surged by 56,168.29% in 2023.
  • Altimmune's Non-cash Items (Quarterly) stood at $8.5 million in 2021, then skyrocketed by 204.07% to $25.7 million in 2022, then tumbled by 34.23% to $16.9 million in 2023, then plummeted by 78.20% to $3.7 million in 2024, then tumbled by 74.13% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $4.3 million for Q2 2025, and $4.3 million during Q1 2025.